Keyphrases
Glycogen Storage Disease
86%
Fanconi-Bickel Syndrome
36%
Value-based Care
33%
Repurposing
33%
Empagliflozin
33%
Benefit-risk Assessment
33%
Des-gamma-carboxy Prothrombin
33%
Continuous Glucose Monitoring
33%
Monitoring Metrics
33%
Liver Glycogen
33%
Ketotic Hypoglycemia
33%
Retrospective Observational Study
33%
Single Center
33%
Ex Vivo Model
33%
Precision-cut Liver Slices
33%
Glucose Production
33%
Hepatic Glucose Production
33%
Pathogen-reduced Platelets
33%
Netherlands
16%
Austria
16%
Cost Savings
16%
Inborn Errors of Metabolism
13%
Mirasol
12%
Health Systems
11%
Neutrophil Dysfunction
11%
Carer Perspectives
11%
Budget Impact Analysis
11%
Healthy Individuals
11%
Time below Range
8%
Glycogenolysis
6%
Dibutyryl-cAMP
6%
Forskolin
6%
Isotope Tracing
6%
Dihydroxyacetone
6%
Fasting Hypoglycemia
6%
Gluconeogenesis
6%
SLC37A4
6%
Lactate Secretion
6%
Glucose-6-phosphate Transporter
6%
13C Isotope
6%
Glucogenic Precursors
6%
Pharmacological Inhibitors
6%
Pharmacoeconomics
5%
Two-country
5%
Value Creation
5%
Granulocyte Colony-stimulating Factor (G-CSF)
5%
Personal Outcomes
5%
Clinical Outcomes
5%
Total Annual Cost
5%
Analysis Sensitivity
5%
Medicine and Dentistry
Glycogen Storage Disease
100%
Empagliflozin
66%
Hypoglycemia
37%
Des-Gamma Carboxyprothrombin
33%
Kidney Tubule Disorder
33%
Sodium Glucose Cotransporter 2 Inhibitor
33%
Hepatocellular Carcinoma
33%
Observational Study
33%
Thrombocyte Transfusion
33%
Pathogen
33%
Prematurity
33%
Tumor Marker
20%
Health Care Cost
16%
Health Care
11%
Neutrophil
11%
Urinary System
8%
Neonatal Intensive Care Unit
7%
Fetal Antigen
6%
Liver Transplantation
6%
Alpha-Fetoprotein
6%
Granulocyte Colony Stimulating Factor
5%
Neutropenia
5%
Quality of Life
5%
Symptom
5%
Diet Therapy
5%
Glycemic Control
5%
Pharmacology, Toxicology and Pharmaceutical Science
Glycogen Storage Disease
100%
Empagliflozin
66%
Repurposing
66%
Hypoglycemia
37%
Syndrome
35%
Sodium Glucose Cotransporter 2 Inhibitor
33%
Decarboxyprothrombin
33%
Liver Cell Carcinoma
33%
Kidney Tubule Disorder
33%
Observational Study
33%
Prematurity
33%
Infectious Agent
33%
Tumor Marker
20%
Fetal Antigen
6%
Alpha Fetoprotein
6%
Granulocyte Colony Stimulating Factor
5%
Pharmacoeconomics
5%
Symptom
5%
Neutropenia
5%
